Stockholm 17:30
-0,40% Idag
+4,44% Sedan årsskifte
-0,01% OMXSPI

2017-12-11 08:30:00

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan


Oasmia Pharmaceutical AB
Inside information

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan

Uppsala, Sweden, 2017-12-11 08:30 CET (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical
AB (NASDAQ: OASM), a developer of a new generation of drugs within human and
veterinary oncology, announced today that it has received marketing approval
for Paclical in Kazakhstan. Paclical is the first water-soluble cancer drug
with paclitaxel to receive a market authorization. Paclical will be sold
through Hetero Group and is planned to be launched during the first half of
2018.

Paclical, which has the name Apealea in Europe, is a novel formulation of
paclitaxel based on Oasmia’s proprietary XR17 technology. It was approved for
treatment of epithelial ovarian cancer. XR17 is non-toxic and forms water
soluble nanoparticles with paclitaxel.

“The relationship established this year with Hetero Group grows further
according to our plan with this approval,” says Julian Aleksov, Executive
Chairman at Oasmia Pharmaceutical. “We are pleased to see this expansion into
Kazakhstan, a country that we are confident will benefit from an additional and
high-quality treatment now made available to physicians and patients. We look
forward to Hetero’s work in generating sales in the region, and most
importantly to Paclical making a difference in the lives of patients and their
families.”



Notes to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology. The
company’s product development aims to create and manufacture novel nanoparticle
formulations and drug-delivery systems based on well-established cytostatics
which, in comparison with current alternatives, show improved properties,
reduced side-effects, and expanded applications. The company’s product
development is based on its proprietary in-house research and company patents.
Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange
(OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).


For more information:
Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com


Attached html: HTML
Attached pdf: PDF